Embarrassment may be costing lives: study probes why women delay cancer checks
NCT ID NCT04839874
First seen Jun 27, 2026 ยท Last updated Jun 27, 2026
Summary
This study interviewed 12 women diagnosed with gynaecological cancers (ovarian, womb, cervical, vulval, or vaginal) to understand what made them seek help or delay. Researchers focused on embarrassment and other barriers to early doctor visits. The goal is to use these insights to encourage earlier diagnosis and reduce deaths.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
12 people
The number who actually took part.
- Started
-
Mar 2021
- Finished
-
Mar 2023
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Women who have been diagnosed with a gynaecological cancer
- Ages
-
18 to 100 years
- Sex
-
Female participants only
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Clinical diagnosis of gynaecological cancer Exclusion Criteria: * Non-English speaking participants * Cognitive impairment * Terminal stage of illness * Diagnosis through screening programmes
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Cervical cancer are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
NHS Grampian
Aberdeen, Aberdeen City, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Operationalising multifactorial ovarian cancer risk assessment using the CanRisk tool versus standard practices.
- Can a new drug shrink advanced solid tumors?
- Can ultrasound sharpen the surgical map for ovarian cancer near the liver?
- Can a new drug shrink tumors that resist standard care?
- Can protein patterns in stored tumors point to new treatment targets?
- Blood vessel cells in a simple blood test may predict ovarian cancer therapy success